Status:
COMPLETED
First-in-Human Exploratory Single Ascending Dose of GLPG0974
Lead Sponsor:
Galapagos NV
Conditions:
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this exploratory first-in-human study is to evaluate the amount of GLPG0974 present in the blood (pharmacokinetics) after single oral doses of GLPG0974 given to healthy subjects. Furth...
Eligibility Criteria
Inclusion
- Healthy male, age 18-50 years
- BMI between 18-30 kg/m2
Exclusion
- Any condition that might interfere with the procedures or tests in this study
- Drug or alcohol abuse
- Smoking
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01496937
Start Date
December 1 2011
End Date
February 1 2012
Last Update
April 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS Stuivenberg
Antwerp, Antwerp, Belgium